Elizabeth Nielson, PhD

Dr. Elizabeth Nielson is CEO and co-founder of Fluence. Her focus as a psychologist is on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson was a Site Co-Principal Investigator and therapist for an FDA-approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder, and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

Speaker Disclosures:

Financial: Elizabeth Nielson is CEO and co-founder of Fluence International, Inc. She holds stock or stock options in AtaiBeckley, Tactogen, and GoodCap. Elizabeth Nielson receives a speaking honorarium from PESI, Inc.

Non-financial: Elizabeth Nielson has no relevant non-financial relationships.